Endocrinology, Diabetes & Metabolism · Nov 15, 2026

Efficacy of SGLT2 Inhibitors With or Without Metformin Compared With Metformin Alone in Women With Polyendocrine Metabolic Ovarian Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

By Mohamed AA, Feteih M, Ahmed ME et al.

Background: Polycystic ovary syndrome (PCOS), recently redefined as polyendocrine metabolic ovarian syndrome (PMOS), is a common endocrine disorder of reproductive‐age women. Metformin remains first‐line therapy, whereas sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have emerged for their cardiometabolic effects. This study compared SGLT2 inhibitors, alone or with metformin, versus metformin alone in PMOS. Methods: We performed a PRISMA‐guided systematic review and meta‐analysis of randomized controlled trials from PubMed, Scopus, Web of Science, Cochrane CENTRAL and Embase. Two reviewers independently screened, extracted data, assessed risk of bias (Cochrane RoB 2) and rated certainty using GRADE. Continuous outcomes were pooled as mean differences (MD) with 95% confidence intervals (CI) under a random‐effects model; heterogeneity was assessed with I ² . Results: Five trials (292 women) were included. SGLT2 inhibitors did not differ significantly from metformin in body weight (MD = −2.06 kg; 95% CI −5.79 to 1.68) or BMI (MD = −0.34 kg/m ² ; 95% CI −0.78 to 0.10), or most hormonal, glycemic and anthropometric outcomes. However, they significantly reduced triglycerides (MD = −0.21 mmol/L; 95% CI −0.38 to −0.05) and diastolic blood pressure (MD = −1.79 mmHg; 95% CI −2.57 to −1.01), with a small increase in systolic blood pressure (MD = 0.97 mmHg; 95% CI 0.11–1.83). Certainty of evidence ranged from low to high. Conclusion: SGLT2 inhibitors, alone or with metformin, did not differ significantly from metformin across most metabolic and endocrine outcomes, with modest benefits on triglycerides and diastolic blood pressure. Metformin remains first‐line therapy; SGLT2 inhibitors may be considered in selected patients pending larger trials.

doi.org/10.1002/edm2.70397Open accessPubMed 43035953Interventions

AgingResearch.News